Enclomiphene myths vs facts: what the evidence really says

Last updated 2026-07-30

Is enclomiphene FDA-approved?

No. This is the single biggest myth out there, and it's worth killing first. Enclomiphene citrate went through clinical trials under the brand name Androxal, developed by Repros Therapeutics, aiming for FDA approval as a treatment for secondary hypogonadism in men. It never got there. Repros submitted data from Phase 3 trials in the early 2010s. The FDA's response, described in the company's own SEC filings and investor communications, was that the efficacy and safety data package wasn't sufficient to support approval ^[1]. Repros discontinued the program. No other company has picked it up and pushed it through to an approved New Drug Application since. What's sold today as "enclomiphene" comes from compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which allows compounding based on a prescription for an individual patient (503A) or by an outsourcing facility (503B), without the drug itself being FDA-approved for that use ^[2]. That's meaningfully different from a generic drug, which is FDA-approved and manufactured to a fixed, tested formula. Compounded enclomiphene is legal to prescribe and dispense, but it hasn't cleared the same bar. If a website or seller tells you enclomiphene is "FDA-approved for TRT," that's flatly wrong. Say it's compounded and prescribed off an approved framework for compounding, not that the drug itself is approved.

Does enclomiphene actually preserve fertility, or is that a myth?

It's not a myth, but it's also not a guarantee, and the evidence base is thinner than the marketing suggests. Here's the actual mechanism and what's been measured. Enclomiphene is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors at the hypothalamus, which the brain reads as "estrogen is low," so it ramps up GnRH pulsing, which raises LH and FSH from the pituitary ^[3]. LH stimulates the testes to make testosterone; FSH, alongside intratesticular testosterone, drives spermatogenesis. Because the testes stay switched on and keep producing testosterone locally at high concentration, sperm production and testicular volume tend to be preserved. Exogenous TRT (injections, gels, pellets) works the opposite way: it supplies testosterone from outside, which the hypothalamus reads as "testosterone is already high," so it shuts down GnRH, LH, and FSH. Intratesticular testosterone, which needs to be roughly 100 times higher than blood levels to sustain sperm production, collapses. That's why TRT reliably suppresses sperm counts, sometimes down to azoospermia, in a large share of men ^[4]. The fertility-preservation case for enclomiphene rests on small studies. A published Phase 2 trial comparing enclomiphene citrate to testosterone gel in men with secondary hypogonadism found enclomiphene raised testosterone while maintaining LH, FSH, and sperm parameters, whereas the testosterone gel group saw LH and FSH suppressed ^[5]. That's a real, mechanistically-consistent finding. It is not the same as a large trial proving that men on enclomiphene, followed for years, have better pregnancy rates or semen analyses than untreated men or men on clomiphene. Nobody has run that trial. So: preserving LH/FSH signaling is well-documented; preserving actual live-birth fertility outcomes is a reasonable inference, not a proven endpoint. For a fuller before/after picture including testicular size, see enclomiphene before and after.

Is enclomiphene the same thing as clomiphene?

No, and mixing these up is one of the most common mistakes people make. Clomiphene citrate (brand name Clomid) is actually a 50/50 mixture of two isomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer) ^[6]. Enclomiphene is the isomer that does most of the anti-estrogenic, LH/FSH-raising work at the hypothalamus. Zuclomiphene has a much longer half-life (it can persist in the body for weeks) and behaves more like a weak estrogen agonist in some tissues, which some researchers think contributes to side effects like mood changes and visual disturbances reported with clomiphene ^[3]. The pitch for isolating enclomiphene alone was that you'd get the testosterone-raising, fertility-friendly effect without zuclomiphene along for the ride. That's the whole premise behind the Androxal development program. Whether isolated enclomiphene actually produces fewer side effects than clomiphene in practice hasn't been settled by a large head-to-head trial; it's a plausible pharmacological argument backed by smaller studies, not a closed case. Clomiphene is FDA-approved, but only for female infertility, not for male hypogonadism. When a doctor prescribes clomiphene for a man's testosterone, that's also off-label use of an approved drug, a different regulatory situation than prescribing compounded enclomiphene.

Does enclomiphene shrink your testicles like TRT does?

The mechanistic answer is that it shouldn't, and that's the main draw for men who want testosterone therapy without the cosmetic and reproductive tradeoffs of injections. Testicular volume depends heavily on ongoing LH stimulation and intratesticular testosterone production; when TRT suppresses LH, the testes literally have less to do and can shrink over months. Because enclomiphene raises LH rather than suppressing it, testicular volume is expected to hold steady or, in men starting from a suppressed baseline, even recover. The Phase 2 trial data referenced above showed maintained LH and FSH alongside testosterone increases, consistent with maintained testicular function ^[5]. But long-term imaging or ultrasound-confirmed volume data over multiple years, across a large cohort, isn't something the current literature has published. The claim "no shrinkage" is a reasonable extrapolation from hormone data, not a directly measured, long-term outcome in a big study.

What are the real side effects, and which claimed side effects are overblown?

Real, reported side effects from clinical trial data on enclomiphene include headache, and in some men, effects on mood and vision that echo what's seen with clomiphene, though generally described as less frequent given the absence of zuclomiphene ^{[5] [3]}. Because it's a SERM affecting estrogen receptors broadly, more than at the hypothalamus, some men report joint discomfort or mild vision disturbances, which is also documented with the broader SERM class. What gets overblown online: claims that enclomiphene is risk-free or "completely safe long-term." Nobody has published large, multi-year safety data on enclomiphene specifically, because it never completed the approval process that would have generated that dataset. The FDA's own concern with the Androxal submission was about the adequacy of the safety and efficacy package, not that the drug looked obviously dangerous ^[1]. That's a meaningfully different message than "it's safe," and it's also different from "it's dangerous." It's closer to "the long-run data doesn't exist at the scale regulators wanted." Another overstated claim: that enclomiphene has zero cardiovascular risk profile compared to TRT. TRT's cardiovascular risk picture is itself debated and evolving, with the FDA requiring label updates about possible cardiovascular risk in 2015 ^[7]. Enclomiphene hasn't been tested in comparably large cardiovascular outcome trials, so there's no head-to-head data to make a confident safety comparison either way. For a balanced weighing of tradeoffs, see enclomiphene pros and cons.

Does enclomiphene work for everyone with low testosterone?

No, and this is a myth worth correcting directly. Enclomiphene works by stimulating a hypothalamic-pituitary-testicular axis that still has functioning parts. It's built for secondary (hypogonadotropic) hypogonadism, where the testes are capable of producing testosterone but aren't getting enough LH/FSH signal, often due to age-related changes, obesity, opioid use, or pituitary/hypothalamic issues. It is not expected to work well for primary hypogonadism, where the testes themselves are damaged or nonfunctional (from conditions like Klinefelter syndrome, chemotherapy, or testicular injury). In primary hypogonadism, LH and FSH are often already elevated because the pituitary is trying (and failing) to get a response from testes that can't respond. Giving more stimulation via enclomiphene doesn't fix testes that can't respond to begin with. Diagnosing which type of hypogonadism a man has requires actual lab work: total and free testosterone, LH, FSH, sometimes prolactin and other pituitary hormones, usually drawn in the morning on more than one occasion given normal daily variation ^[4]. This isn't something to self-diagnose from symptoms alone.

How does enclomiphene compare to TRT in terms of results and speed?

They both raise testosterone, but the mechanism, timeline, and side-effect tradeoffs differ meaningfully. | Factor | Enclomiphene | Exogenous TRT (injections/gels) |

Is enclomiphene just a bodybuilding or performance-enhancing drug, or is it legitimate medicine?

Both framings get thrown around, and neither is quite right on its own. Enclomiphene is a prescription medication that requires a diagnosis and a prescriber, prescribed off the compounding framework described above ^[2]. It's used in legitimate hormone therapy for men with documented secondary hypogonadism, and it's also used, sometimes without a real diagnosis, by people who want to raise testosterone for physique or athletic reasons, occasionally as "post-cycle therapy" after anabolic steroid use to try to restart natural testosterone production. That second use case is not what any clinical trial studied. The Androxal trials enrolled men with diagnosed low testosterone from typical causes, not men recovering from steroid-induced suppression ^[5]. Using it that way isn't necessarily unreasonable pharmacologically, since the LH/FSH-stimulating mechanism is the same, but there's no clinical trial data on dosing, timeline, or success rate specifically for that population. Anyone buying it off gray-market sources for that purpose is doing so with zero quality control and zero physician oversight, which is a different risk profile from a prescribed, provider-reviewed product.

How much does enclomiphene cost, and is the price a scam red flag?

Compounded enclomiphene prices vary widely because it's compounded, not manufactured at fixed scale under one NDC number. Reported cash prices from telehealth and compounding pharmacy sources commonly run somewhere in the range of $50 to $150 per month, though this shifts with dose, pharmacy, and whether it's bundled with a telehealth consult fee. There's no single "correct" price because there's no single manufacturer setting one. A price that's dramatically lower than that range, especially from an unlicensed overseas seller with no prescription requirement, is a bigger red flag than a price that's higher. Legitimate compounding pharmacies operating under 503A or 503B have real overhead: USP-set standards for compounding quality, testing, and record-keeping . Skipping a prescription and lab work to save money on enclomiphene skips the exact monitoring (estradiol, LH, FSH, liver function) that catches problems early.

What should you actually do before starting enclomiphene?

Get real labs first. That means morning total testosterone, ideally confirmed on two separate days given normal fluctuation, plus LH and FSH to determine whether you're dealing with primary or secondary hypogonadism, and often estradiol and prolactin too ^[4]. Skipping this step means you don't actually know if enclomiphene is the right tool. Work with a prescriber who orders follow-up labs, more than an initial questionnaire. Testosterone, LH, FSH, and estradiol at roughly 4 to 8 weeks after starting is a reasonable check to confirm the axis is responding the way the mechanism predicts. Enclomiphene Direct's role here is connecting men with provider-reviewed access to compounded enclomiphene, filled through a licensed pharmacy partner, not manufacturing or compounding it themselves. That distinction matters: the prescribing and lab monitoring should come from a real clinician relationship, and the product should come from a licensed pharmacy, not a warehouse with no oversight. If you're still weighing whether this category of treatment fits your situation at all, is enclomiphene worth it and enclomiphene reviews walk through the honest tradeoffs and what real users report, separate from the myths covered here.

Frequently asked questions

Is enclomiphene FDA-approved for low testosterone?

No. The Androxal development program sought FDA approval for enclomiphene in men with secondary hypogonadism but didn't reach it; Repros Therapeutics discontinued the program after the FDA found the data package insufficient. What's available today is compounded by pharmacies under Section 503A/503B rules, not sold as an approved drug product.

Does enclomiphene really preserve fertility better than TRT?

Small trials show enclomiphene preserves LH, FSH, and sperm parameters while raising testosterone, unlike TRT which suppresses LH/FSH and often sperm count. That's a real, mechanistically sound finding. No large trial has confirmed long-term pregnancy or live-birth outcomes specifically, so treat 'preserves fertility' as well-supported for hormone/sperm markers, not as a guaranteed reproductive outcome.

Is enclomiphene the same as Clomid?

No. Clomid (clomiphene citrate) is a 50/50 mix of two isomers: enclomiphene and zuclomiphene. Enclomiphene alone is thought to drive most of the testosterone-raising effect, while zuclomiphene has a much longer half-life and may contribute more to certain side effects. Isolating enclomiphene was the whole premise of the (unapproved) Androxal program.

Can enclomiphene cause testicular shrinkage like TRT?

It shouldn't, mechanistically, since it raises rather than suppresses LH, which is what keeps the testes stimulated and sized normally. This is supported by hormone data from small trials, but no large, multi-year study has directly measured testicular volume over time on enclomiphene, so call this a well-reasoned expectation, not a proven long-term outcome.

What are the real side effects of enclomiphene?

Reported side effects include headache, and, less commonly, mood changes and visual disturbances, similar to but generally reported as less frequent than with clomiphene, likely because zuclomiphene is absent. No large-scale, multi-year safety dataset exists because the drug never completed FDA approval, so long-term risk isn't fully quantified.

Does enclomiphene work if you have primary hypogonadism?

Generally no. Enclomiphene stimulates the pituitary to release more LH and FSH, which only helps if the testes can actually respond to that signal. In primary hypogonadism the testes themselves are impaired, so more stimulation doesn't produce more testosterone. Lab work distinguishing primary from secondary hypogonadism is necessary before starting.

Is compounded enclomiphene legal?

Yes, when prescribed and dispensed through licensed pharmacies operating under FDA's compounding framework (Sections 503A and 503B of the Food, Drug, and Cosmetic Act), which allow patient-specific or outsourcing-facility compounding without full FDA approval of the specific drug for that use. Buying from unlicensed sellers without a prescription isn't the same legal situation.

How much does enclomiphene typically cost per month?

Reported cash prices commonly fall somewhere between roughly $50 and $150 per month depending on dose, pharmacy, and whether telehealth consultation fees are bundled in. There's no fixed manufacturer price since it's compounded rather than mass-produced under one approved product code.

Can women take enclomiphene?

Enclomiphene isn't approved or marketed for female use; clomiphene citrate (which contains enclomiphene plus zuclomiphene) is the FDA-approved option for female ovulation induction. Enclomiphene alone hasn't been developed or studied for that indication, so it isn't the standard choice for women's fertility treatment.

How long does it take to see results from enclomiphene?

Hormone changes, including LH, FSH, and testosterone shifts, typically show up on labs within 2 to 4 weeks of starting, based on trial monitoring schedules. Symptom changes (energy, libido, mood) reported by users often take longer, commonly 6 to 12 weeks, though individual response varies and hasn't been mapped by a large outcomes study.

Is enclomiphene safer than TRT long-term?

There's no head-to-head, large-scale, long-term safety trial comparing them directly, so a confident answer either way isn't supported by current evidence. TRT has documented cardiovascular label warnings from the FDA; enclomiphene simply hasn't been studied at that scale, which is a data gap, not proof of superior safety.

Why did enclomiphene (Androxal) fail to get FDA approval?

Repros Therapeutics' regulatory disclosures indicate the FDA found the submitted Phase 3 efficacy and safety data insufficient to support approval for treating secondary hypogonadism, leading the company to discontinue the program rather than pursue it further. It wasn't pulled for a specific safety scandal; the data package simply didn't clear the bar.

Sources

1. Repros Therapeutics, SEC Form 8-K disclosure on Androxal FDA response: FDA found the Androxal (enclomiphene) data package insufficient for approval, leading to program discontinuation
2. U.S. FDA, Human Drug Compounding under Sections 503A and 503B of the FD&C Act: Compounding pharmacies operate under 503A/503B provisions allowing compounded drugs without standard FDA approval
3. Kim ED et al., 'Enclomiphene citrate for the treatment of secondary hypogonadism,' Expert Opin Pharmacother, PubMed: Enclomiphene acts as an estrogen receptor antagonist at the hypothalamus, raising LH and FSH
4. Endocrine Society, Testosterone Therapy in Men with Hypogonadism: Clinical Practice Guideline: Exogenous testosterone therapy suppresses LH/FSH and can suppress spermatogenesis, sometimes to azoospermia
5. Wiehle RD et al., 'Enclomiphene citrate stimulates testosterone production while preventing oligospermia,' J Sex Med, PubMed: Phase 2 trial data showing enclomiphene raised testosterone while maintaining LH, FSH, and sperm parameters compared to testosterone gel
6. DrugBank / NIH PubChem, Clomiphene citrate composition: Clomiphene citrate is a mixture of enclomiphene and zuclomiphene isomers
7. U.S. FDA Drug Safety Communication, testosterone products and cardiovascular risk labeling, 2015: FDA required label updates in 2015 addressing possible cardiovascular risk with testosterone products